References
- Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. Annu Rev Immunol. 2004;22:891-928. https://doi.org/10.1146/annurev.immunol.22.012703.104543
- Oda Y, Yamamoto H, Tamiya S, et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol. 2006;19:738-45. https://doi.org/10.1038/modpathol.3800587
- Chinni SR, Yamamoto H, Dong Z, Sabbota A, Bonfi l RD, Cher ML. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res. 2008;6:446-57. https://doi.org/10.1158/1541-7786.MCR-07-0117
- Müller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-6. https://doi.org/10.1038/35065016
- Spano JP, Andre F, Morat L, et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004;15:613-7. https://doi.org/10.1093/annonc/mdh136
- Scala S, Ottaiano A, Ascierto PA, et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res. 2005;11:1835-41. https://doi.org/10.1158/1078-0432.CCR-04-1887
- Koishi K, Yoshikawa R, Tsujimura T, et al. Persistent CXCR4 expression aft er preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World J Gastroenterol. 2006;12:7585-90. https://doi.org/10.3748/wjg.v12.i47.7585
- Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol. 2006;103:226-33. https://doi.org/10.1016/j.ygyno.2006.02.036
- Azenshtein E, Luboshits G, Shina S, et al. Th e CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62:1093-102.
- Fan TM, Barger AM, Fredrickson RL, Fitzsimmons D, Garrett LD. Investigating CXCR4 expression in canine appendicular osteosarcoma. J Vet Intern Med. 2008;22:602-8. https://doi.org/10.1111/j.1939-1676.2008.0089.x
- Laverdiere C, Hoang BH, Yang R, et al. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 2005;11:2561-7. https://doi.org/10.1158/1078-0432.CCR-04-1089
- Perissinotto E, Cavalloni G, Leone F, et al. Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 2005;11:490-7.
- Unni KK, Dahlin DC. Grading of bone tumors. Semin Diagn Pathol. 1984;1:165-72.
- Paoletti S, Borzi RM, Mazzetti I, et al. Human osteosarcoma cells release matrix degrading enzymes in response to chemokine activation. Int J Oncol. 2001;18:11-6.
- Libura J, Drukala J, Majka M, et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 2002;100:2597-606. https://doi.org/10.1182/blood-2002-01-0031
- Murakami T, Maki W, Cardones AR, et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 2002;62:7328-34.
- Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604-12. https://doi.org/10.1158/0008-5472.CAN-04-1844
- Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 2002;62:1832-7.
- Bai S, Wang D, Klein MJ, Siegal GP. Characterization of CXCR4 expression in chondrosarcoma of bone. Arch Pathol Lab Med. 2011;135:753-8.
- de Nigris F, Rossiello R, Schiano C, et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/ angiogenesis and metastasis. Cancer Res. 2008;68:1797-808. https://doi.org/10.1158/0008-5472.CAN-07-5582
- Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res. 2002;62:7203-6.
- Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004;14:171-9. https://doi.org/10.1016/j.semcancer.2003.10.003
- Gobert M, Treilleux I, Bendriss-Vermare N, et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infi ltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69:2000-9. https://doi.org/10.1158/0008-5472.CAN-08-2360
- von Luettichau I, Nathrath M, Burdach S, Huss R, Segerer S, Nelson PJ. Mononuclear infi ltrates in osteosarcoma and chemokine receptor expression. Clin Cancer Res. 2006;12:5253-4. https://doi.org/10.1158/1078-0432.CCR-06-0785
- Takenaga M, Tamamura H, Hiramatsu K, et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun. 2004;320:226-32. https://doi.org/10.1016/j.bbrc.2004.05.155
- Kim SY, Lee CH, Midura BV, et al. Inhibition of the CXCR4/ CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis. 2008;25:201-11. https://doi.org/10.1007/s10585-007-9133-3